Reporting by Josh Hardman and Noah Smith. Nonprofit psychedelic research organisation Usona Institute has completed its submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) concerning its psilocybin candidate for major depressive disorder (MDD), Psychedelic Alpha understands. It means it’s the second psychedelic NDA under review by the agency at present…
